Thymosin Beta-4 and Actin: Reading a Defined In Vitro Source Record

Research use only. This article does not provide medical, veterinary, dosing, administration, safety, or outcome guidance.

In-vitro actin system reported by Carlier et al.

Carlier et al. examined thymosin beta-4 in actin-assembly experiments across concentrations up to 300 micromolar. The paper distinguishes globular actin (G-actin) from filamentous actin (F-actin) and reports observations for the concentration ranges used in that biochemical system.

Below 20 micromolar, the authors report that thymosin beta-4 behaved as a simple G-actin-sequestering protein. At higher concentrations, they report reduced F-actin depolymerization associated with interaction with F-actin. These are concentration- and actin-state-specific findings from the stated in-vitro experiment.

Methods and readouts in the source

The authors report that the thymosin beta-4-actin complex was incorporated into F-actin at low molar ratios. They also report cross-linking of that complex in F-actin with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The study’s conclusion concerns the reported thymosin beta-4/actin system; it does not provide an analytical result, composition, or lot record for the linked catalogue material.

Terminology source

UniProt accession P62328 identifies the reviewed human protein entry as thymosin beta-4 and lists gene name TMSB4X. The database entry is a terminology reference. It does not establish the identity of the test material in the 1996 study or a separately supplied material.

Related reading

TB-500 and Thymosin Beta-4: Nomenclature, Source Scope and Documentation Review addresses the separate naming boundary between TB-500 and thymosin beta-4.

Separate the assay system from the material listing

Carlier et al. studied thymosin beta-4 in a defined biochemical actin system. Their record distinguishes globular actin (G-actin) from filamentous actin (F-actin), varies the concentration range, and reports how the peptide-actin relationship changes across that range. The observations belong to the proteins, buffers, temperatures, incubation periods, and measurement methods stated in the 1996 paper. They are not an analytical certificate for the linked TB-500 catalogue item.

Read concentration statements with their context

The paper reports simple G-actin sequestration behaviour below 20 micromolar and an interaction with F-actin at higher concentrations, including experiments extending to 300 micromolar. It also reports incorporation of the thymosin beta-4-actin complex into F-actin at low molar ratios and cross-linking with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. These are concentration- and protocol-specific observations. They should not be rewritten as a recommended amount, an administration instruction, or a prediction for another preparation.

Use UniProt as an identity aid

UniProt P62328 is a reviewed human thymosin beta-4 protein entry with the TMSB4X gene name. That record helps normalize the protein name and accession. It does not prove that the 1996 experiment used a particular recombinant or synthetic lot, and it does not resolve the separate naming question of TB-500. Keep the UniProt entry, the primary paper, and the catalogue page as distinct sources with distinct scopes.

Bounded interpretation

A defensible summary states the actin state, concentration range, readout, and author conclusion, then lists what was not measured. The study does not report a catalogue-lot identity, release purity, stability, clinical outcome, or human or veterinary use. A product page does not inherit the paper’s result merely through a shared name. Any claim beyond the defined in-vitro system would require a new direct record.

Research-only boundary: This is a source-reading article, not a laboratory protocol, dosing or administration guide, safety guarantee, therapeutic claim, or purchasing recommendation.

Method fields worth retaining

For the actin experiments, retain whether the measurement concerns polymerization, depolymerization, binding, or cross-linking; the actin state; the peptide-to-actin ratio; concentration; buffer; temperature; and observation time. If the paper reports a range rather than a single value, preserve the range. A later summary should not turn a concentration range into a recommended amount or imply that a different salt form behaves identically.

Publication identity check

Europe PMC indexes PMID 8621582 as Carlier and colleagues’ 1996 Journal of Biological Chemistry article, volume 271, issue 16, pages 9231-9239, DOI 10.1074/jbc.271.16.9231. Keeping those fields with the citation helps distinguish this biochemical record from later cell or animal studies that use the thymosin beta-4 name.

Negative claims are part of the audit

The source does not establish a catalogue lot, release specification, stability profile, clinical outcome, or safety conclusion. Listing those absent fields prevents a reader from treating a well-described in-vitro mechanism as a general product claim. The correct endpoint of this page is a bounded interpretation of one source record.

The actin paper is valuable precisely because it records a concentration-dependent change in interpretation. Preserve that nuance, cite the original figures or methods when available, and avoid compressing the result into a single descriptor such as “binding peptide.”

Document the assay controls and whether the reported interaction was observed directly or inferred from a kinetic or structural readout. If a control is not described, leave that field unreported. This is the only reliable way to preserve the paper’s own uncertainty while keeping the catalogue link informational.

For citation hygiene, keep the 1996 publication date, authors, DOI, and PMID with every quotation. This avoids merging the defined actin record with later claims that use the thymosin beta-4 name but test a different system.